Conditions: Diabetic Retinopathy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 203
Healthy volunteers: no

Brief summary:
To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment. Patients must be off study drug for 6 to 18 months from completion of B7A-MC-MBCM before beginning B7A-MC-MBDV. Additional data will be gathered to determine the long-term safety and effect of ruboxistaurin on vision.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Ruboxistaurin
Intervention descriptions: intervention 1: 32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.

Protocol document: